These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 18718055)

  • 1. [Relationships of serum selenium, VEGF and sFas levels in leukemia patients].
    Wang Y; Liu FQ; Wu YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):759-62. PubMed ID: 18718055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation and Significance of Urinary Soluble Fas and Vascular Endothelial Growth Factor in Bladder Urothelial Cancer.
    Yang H; Wang Z; Guo Y; Wang Z
    Dis Markers; 2015; 2015():383509. PubMed ID: 26798188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
    Yuan BJ; Liu ZZ; Ding XR; Zou JM
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on the role of angiogenesis and related factors in leukemias].
    Zhang Y; Gu J; Wang M; Ma L; Wang XL; He B; Sun M
    Zhonghua Xue Ye Xue Za Zhi; 2005 Mar; 26(3):175-8. PubMed ID: 15946533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.
    Chen DY; Lan JL; Lin FJ; Hsieh TY
    Clin Rheumatol; 2007 Mar; 26(3):393-400. PubMed ID: 16972019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of osteopontin and VEGF in acute leukemia and their relationship with angiogenesis].
    Wang HL; Ruan LH; Zhao XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):926-9. PubMed ID: 21867616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of bFGF and VEGF in acute leukemia and its effects on HL-60 cell growth].
    Zhang WP; Chun XQ; Zhang YQ; Liang R; Li YH; Gao GX; Zhu HF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):91-4. PubMed ID: 15748443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
    Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
    Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T; Toi M; Tominaga T
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
    Konno R; Takano T; Sato S; Yajima A
    Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum sFas, leptin, and VEGF in patients with ovarian cancer and benign tumors.
    Vysotskii MM; Digaeva MA; Kushlinskii NE; Abbasova SG; Laktionov KP; Ermilova VD; Bakhoeva KA; Kryuk YV; Manukhin IB
    Bull Exp Biol Med; 2009 Nov; 148(5):810-4. PubMed ID: 20396799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of CD4(+)CD25(+)Treg cells, sFas and sFasL in peripheral blood of patients with autoimmune thrombocytopenic purpura].
    Jia RP; Zhao XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1264-7. PubMed ID: 22040985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study of serum sFas in patients with hepatocellular cancer and chronic hepatitis].
    Chen J; Zheng XH; Tang XP
    Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):173-4. PubMed ID: 12536662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
    Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
    Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies].
    Kacprzyk F
    Pol Arch Med Wewn; 2002 Sep; 108(3):843-7. PubMed ID: 12600180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of VEGF and its receptor in refractory leukemia cells.
    Wang L; Zhang W; Ding Y; Xiu B; Li P; Dong Y; Zhu Q; Liang A
    Int J Clin Exp Pathol; 2015; 8(5):5282-90. PubMed ID: 26191229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.